Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.

Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, Bijou F, Houot R, Boyle E, Gressin R, Nicolas-Virelizier E, Barrie M, Moluçon-Chabrot C, Lelez ML, Clavert A, Coisy S, Leruez S, Touitou V, Cassoux N, Daniau M, Ertault de la Bretonnière M, El Yamani A, Ghesquières H, Hoang-Xuan K.

Eur J Cancer. 2019 Aug;117:121-130. doi: 10.1016/j.ejca.2019.05.024. Epub 2019 Jul 3.

PMID:
31279304
2.

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.

Blez D, Blaize M, Soussain C, Boissonnas A, Meghraoui-Kheddar A, Menezes N, Portalier A, Combadière C, Leblond V, Ghez D, Fekkar A.

Haematologica. 2019 Jun 6. pii: haematol.2019.219220. doi: 10.3324/haematol.2019.219220. [Epub ahead of print]

3.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A; LOC Network.

Neuro Oncol. 2019 May 17. pii: noz088. doi: 10.1093/neuonc/noz088. [Epub ahead of print]

PMID:
31102405
4.

Role of lenalidomide maintenance in primary CNS Lymphoma. Reply to the Letter to the Editor "maintenance lenalidomide in primary CNS lymphoma" by J. L. Rubenstein, et al.

Ghesquieres H, Soussain C.

Ann Oncol. 2019 May 16. pii: mdz161. doi: 10.1093/annonc/mdz161. [Epub ahead of print] No abstract available.

PMID:
31095293
5.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
6.

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C.

Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032.

PMID:
30698644
7.

(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.

Collignon A, Houillier C, Ahle G, Chinot O, Choquet S, Schmitt A, Agape P, Soussain C, Hoang-Xuan K, Tabouret E.

Ann Hematol. 2019 Apr;98(4):915-922. doi: 10.1007/s00277-018-3564-6. Epub 2018 Dec 7.

PMID:
30535802
8.

Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.

Pouzoulet F, Alentorn A, Royer-Perron L, Assayag F, Mokhtari K, Labiod D, Le Garff-Tavernier M, Daniau M, Menet E, Peyre M, Schnitzler A, Guegan J, Davi F, Hoang-Xuan K, Soussain C.

Blood Cells Mol Dis. 2019 Mar;75:1-10. doi: 10.1016/j.bcmd.2018.11.005. Epub 2018 Nov 16.

PMID:
30502564
9.

New insights in radiation-induced leukoencephalopathy: a prospective cross-sectional study.

Bompaire F, Lahutte M, Buffat S, Soussain C, Ardisson AE, Terziev R, Sallansonnet-Froment M, De Greslan T, Edmond S, Saad M, Nioche C, Durand T, Alamowitch S, Xuan KH, Delattre JY, Renard JL, Taillia H, Chargari C, Psimaras D, Ricard D.

Support Care Cancer. 2018 Dec;26(12):4217-4226. doi: 10.1007/s00520-018-4296-9. Epub 2018 Jul 7.

PMID:
29982900
10.

Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

Birsen R, Blanc E, Willems L, Burroni B, Legoff M, Le Ray E, Pilorge S, Salah S, Quentin A, Deau B, Franchi P, Vignon M, Mabille L, Nguyen C, Kirova Y, Varlet P, Edjlali M, Dezamis E, Hoang-Xuan K, Soussain C, Houillier C, Damotte D, Pallud J, Bouscary D, Tamburini J.

Oncotarget. 2018 Mar 30;9(24):16822-16831. doi: 10.18632/oncotarget.24706. eCollection 2018 Mar 30.

11.

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association.

Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23.

12.

Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.

Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, Fornecker LM, Houot R, Gastinne T, Soussain C, Malak S, Lemal R, Delette C, Ibrahim A, Gac AC, Reboursière E, Vilque JP, Bekadja MA, Casasnovas RO, Gressin R, Guidez S, Coso D, Herbaux C, Yakoub-Agha I, Bouabdallah K, Durot E, Damaj G.

Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.

13.

Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.

Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, Le Ray E, Pilorge S, Deau B, Franchi P, Vignon M, Kirova Y, Edjlali M, Houillier C, Soussain C, Varlet P, Dezamis E, Damotte D, Bouscary D, Tamburini J.

Haematologica. 2018 Jul;103(7):e296-e299. doi: 10.3324/haematol.2017.185843. Epub 2018 Feb 22. No abstract available.

14.

Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.

Bruno A, Labreche K, Daniau M, Boisselier B, Gauchotte G, Royer-Perron L, Rahimian A, Lemoine F, de la Grange P, Guégan J, Bielle F, Polivka M, Adam C, Meyronet D, Figarella-Branger D, Villa C, Chrétien F, Eimer S, Davi F, Rousseau A, Houillier C, Soussain C, Mokhtari K, Hoang-Xuan K, Alentorn A.

Neuro Oncol. 2018 Jul 5;20(8):1092-1100. doi: 10.1093/neuonc/noy019.

15.

Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.

Qiu Y, Li Z, Pouzoulet F, Vishnu P, Copland JA 3rd, Knutson KL, Soussain C, Tun HW.

Br J Haematol. 2018 Nov;183(4):674-678. doi: 10.1111/bjh.15009. Epub 2017 Oct 26. No abstract available.

PMID:
29076134
16.

Optic Nerve Infiltration in Primary Central Nervous System Lymphoma.

Ahle G, Touitou V, Cassoux N, Bouyon M, Humbrecht C, Oesterlé H, Baraniskin A, Soussain C, Nguyen-Them L, Gaultier C, Hoang-Xuan K, Houillier C.

JAMA Neurol. 2017 Nov 1;74(11):1368-1373. doi: 10.1001/jamaneurol.2017.2545.

17.

High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.

Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O, De-Silva D, Cwynarski K, Houillier C, Hoang-Xuan K, Touitou V, Cassoux N, Marolleau JP, Tamburini J, Houot R, Delwail V, Illerhaus G, Soussain C, Kasenda B.

Bone Marrow Transplant. 2017 Aug;52(8):1113-1119. doi: 10.1038/bmt.2017.23. Epub 2017 Apr 24.

18.

Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.

Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO, Vargaftig J, Gaultier C, Touitou V, Martin-Duverneuil N, Cassoux N, Le Garff-Tavernier M, Costopoulos M, Faurie P, Hoang-Xuan K.

J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21.

PMID:
28432587
19.

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO).

Leuk Lymphoma. 2017 Nov;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. Epub 2017 Apr 10.

PMID:
28395585
20.

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K.

Neuro Oncol. 2017 Mar 1;19(3):422-429. doi: 10.1093/neuonc/now238.

21.

Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.

Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K, Soussain C.

Neurology. 2017 Jan 3;88(1):101-102. doi: 10.1212/WNL.0000000000003420. Epub 2016 Nov 18. No abstract available.

PMID:
27864520
22.

How to facilitate early diagnosis of CNS involvement in malignant lymphoma.

Korfel A, Nowosielski M, Pardo-Moreno J, Penalver FJ, Buda G, Bennani H, Costopoulos M, Le Garff-Tavernier M, Soussain C, Schmid M, Orfao JA, Glantz M.

Expert Rev Hematol. 2016 Nov;9(11):1081-1091. Epub 2016 Oct 21. Review.

PMID:
27677656
23.

The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.

Nguyen-Them L, Costopoulos M, Tanguy ML, Houillier C, Choquet S, Benanni H, Elias-Shamieh R, Armand M, Faivre G, Glaisner S, Malak S, Vargaftig J, Hoang-Xuan K, Ahle G, Touitou V, Cassoux N, Davi F, Merle-Béral H, Le Garff-Tavernier M, Soussain C; French LOC Network for CNS Lymphoma.

Eur J Cancer. 2016 Jul;61:69-76. doi: 10.1016/j.ejca.2016.03.080. Epub 2016 May 5.

PMID:
27156226
24.

Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control.

Nguyen DT, Houillier C, Choquet S, Cassoux N, Soussain C, Le Cossec C, Legarf-Tavernier M, Costopoulos M, LeHoang P, Bodaghi B, Omuro A, Hoang-Xuan K, Touitou V.

Ophthalmology. 2016 Sep;123(9):2047-50. doi: 10.1016/j.ophtha.2016.03.043. Epub 2016 Apr 29. No abstract available.

PMID:
27137876
25.

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.

Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, Bouabdallah K, Morschhauser F, Le Gouill S, Salles GA, Hoang-Xuan K, Choquet S, Marchand T, Laurent C, Pangault C, Lamy T.

Ann Oncol. 2016 Jul;27(7):1349-50. doi: 10.1093/annonc/mdw138. Epub 2016 Mar 21. No abstract available.

PMID:
27002105
26.

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R.

Neuro Oncol. 2016 Sep;18(9):1297-303. doi: 10.1093/neuonc/now033. Epub 2016 Mar 6.

27.

ISOLD: A New Highly Sensitive Interleukin Score for Intraocular Lymphoma Diagnosis.

Costopoulos M, Touitou V, Golmard JL, Darugar A, Fisson S, Bonnemye P, Le Lez ML, Soussain C, Cassoux N, Lamy T, Le Hoang P, Bodaghi B, Merle-Béral H, Le Garff-Tavernier M.

Ophthalmology. 2016 Jul;123(7):1626-8. doi: 10.1016/j.ophtha.2016.01.037. Epub 2016 Mar 3. No abstract available.

28.

Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barrié M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K.

Lancet Haematol. 2015 Jun;2(6):e251-9. doi: 10.1016/S2352-3026(15)00074-5. Epub 2015 Jun 3.

PMID:
26688235
29.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

30.

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

Simon L, Fitsiori A, Lemal R, Dupuis J, Carpentier B, Boudin L, Corby A, Aurran-Schleinitz T, Gastaud L, Talbot A, Leprêtre S, Mahe B, Payet C, Soussain C, Bonnet C, Vincent L, Lissandre S, Herbrecht R, Kremer S, Leblond V, Fornecker LM.

Haematologica. 2015 Dec;100(12):1587-94. doi: 10.3324/haematol.2015.133744. Epub 2015 Sep 18. Review.

31.

Prevalence of hepatitis B virus in primary central nervous system lymphoma.

Faivre G, Thibault V, Tanguy ML, Leblond V, Choquet S, Soussain C, Gonzalez-Aguilar A, Sierra del Rio M, Houillier C, Hoang-Xuan K, Idbaih A.

J Neurooncol. 2015 Oct;125(1):219-21. doi: 10.1007/s11060-015-1879-x. Epub 2015 Aug 14. No abstract available.

PMID:
26272598
32.

TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium.

Bruno A, Alentorn A, Daniau M, Labussière M, Rahimian A, Tabouret E, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Chrétien F, Eimer S, Houillier C, Soussain C, Mokhtari K, Hoang-Xuan K.

Acta Neuropathol. 2015 Sep;130(3):439-40. doi: 10.1007/s00401-015-1461-9. Epub 2015 Jul 21. No abstract available.

PMID:
26195323
33.

Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.

Damaj G, Ivanoff S, Coso D, Ysaebert L, Choquet S, Houillier C, Parcelier A, Abarah W, Marjanovic Z, Gressin R, Garidi R, Diouf M, Gac AC, Dupuis J, Troussard X, Morschhauseur F, Ghesquières H, Soussain C; LYSA and LOC network, France.

Haematologica. 2015 Sep;100(9):1199-206. doi: 10.3324/haematol.2015.126110. Epub 2015 Jul 16.

34.

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma.

Lancet Oncol. 2015 Jul;16(7):e322-32. doi: 10.1016/S1470-2045(15)00076-5. Review.

35.

Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.

Hermet E, Cabrespine A, Guièze R, Garnier A, Tempescul A, Lenain P, Bouabdallah R, Vilque JP, Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Biron P, Legros L, Choufi B, Drenou B, Gorin NC, Bilger K, Tamburini J, Soussain C, Brechignac S, Bay JO; Société Française de Greffe de Moelle et de Thérapie Cellulaire.

J Geriatr Oncol. 2015 Sep;6(5):346-52. doi: 10.1016/j.jgo.2015.04.005. Epub 2015 Jun 23.

PMID:
26116168
36.

Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.

Houillier C, Choquet S, Touitou V, Martin-Duverneuil N, Navarro S, Mokhtari K, Soussain C, Hoang-Xuan K.

Neurology. 2015 Jan 20;84(3):325-6. doi: 10.1212/WNL.0000000000001158. Epub 2014 Dec 19. No abstract available.

PMID:
25527263
37.

Mutational analysis of primary central nervous system lymphoma.

Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K.

Oncotarget. 2014 Jul 15;5(13):5065-75.

38.

[Primary CNS lymphoma--an update].

Soussain C, Houillier C, Choquet S, Hoang-Xuan K.

Bull Cancer. 2014 Mar;101(3):314-24. doi: 10.1684/bdc.2014.1909. Review. French.

PMID:
24691194
39.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C.

Ann Oncol. 2013 Apr;24(4):1032-7. doi: 10.1093/annonc/mds600. Epub 2012 Dec 12.

40.

Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquières H, Gressin R, Delwail V, Taillandier L, Chinot O, Soubeyran P, Gyan E, Choquet S, Houillier C, Soussain C, Tanguy ML, Marie Y, Mokhtari K, Hoang-Xuan K.

Clin Cancer Res. 2012 Oct 1;18(19):5203-11. doi: 10.1158/1078-0432.CCR-12-0845. Epub 2012 Jul 26.

41.

Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.

Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquières H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond V.

Haematologica. 2012 Nov;97(11):1751-6. doi: 10.3324/haematol.2011.060434. Epub 2012 May 11.

42.

[Management of primary central nervous system lymphoma].

Gonzalez-Aguilar A, Houillier C, Soussain C, Hoang-Xuan K.

Rev Neurol (Paris). 2011 Oct;167(10):721-8. doi: 10.1016/j.neurol.2011.08.004. Epub 2011 Sep 8. Review. French.

PMID:
21906768
43.

Neurotoxicity of the CNS: diagnosis, treatment and prevention.

Ricard D, Soussain C, Psimaras D.

Rev Neurol (Paris). 2011 Oct;167(10):737-45. doi: 10.1016/j.neurol.2011.08.005. Epub 2011 Sep 6. Review.

PMID:
21899866
44.

Prophylactic intrathecal chemotherapy in primary CNS lymphoma.

Sierra Del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K.

J Neurooncol. 2012 Jan;106(1):143-6. doi: 10.1007/s11060-011-0649-7. Epub 2011 Jul 8.

PMID:
21739169
45.

Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.

del Rio MS, Choquet S, Hoang-Xuan K, Glaisner S, Fourme E, Janvier M, Soussain C.

J Neurooncol. 2011 Nov;105(2):409-14. doi: 10.1007/s11060-011-0608-3. Epub 2011 Jun 9.

PMID:
21656329
46.

Whole-brain radiotherapy in primary CNS lymphoma.

Ferreri AJ, DeAngelis L, Illerhaus G, O'Neill BP, Reni M, Soussain C, Yahalom J.

Lancet Oncol. 2011 Feb;12(2):118-9; author reply 119-20. doi: 10.1016/S1470-2045(11)70018-3. No abstract available.

PMID:
21277546
47.

Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?

Omuro A, Taillandier L, Chinot O, Sierra Del Rio M, Carnin C, Barrie M, Soussain C, Tanguy ML, Choquet S, Leblond V, Hoang-Xuan K; ANOCEF Group (French Neuro-Oncology Association).

J Neurooncol. 2011 Aug;104(1):323-30. doi: 10.1007/s11060-010-0497-x. Epub 2010 Dec 19.

PMID:
21170569
48.

CNS complications of radiotherapy and chemotherapy.

Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY.

Lancet. 2009 Nov 7;374(9701):1639-51. doi: 10.1016/S0140-6736(09)61299-X. Review.

PMID:
19897130
49.

Primary central nervous system lymphoma: an update.

Soussain C, Hoang-Xuan K.

Curr Opin Oncol. 2009 Nov;21(6):550-8. doi: 10.1097/CCO.0b013e3283310eb3. Review.

PMID:
19684518
50.

Primary CNS lymphoma in immunocompetent patients.

Sierra del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K.

Oncologist. 2009 May;14(5):526-39. doi: 10.1634/theoncologist.2008-0236. Epub 2009 May 11. Review.

Supplemental Content

Loading ...
Support Center